Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

131.04 +0.35 (+0.27%)
Streaming Delayed Price Updated: 10:16 AM EDT, May 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Dexcom Inc

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Dexcom Stock Shows Market Leadership With Jump To 86 RS Rating
Dexcom shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 86. 
Via Investor's Business Daily
Markets Have Another Strong Week As S&P 500 Erases Initial Losses From Russia-Ukraine War
U.S. indices finished mixed Friday to conclude the trading week. Oil prices gained during Friday's session, which has continued to pressure economic sentiment. The S... 
Via Benzinga
Markets Fall In Anticipation Of This Week's Fed Decision
U.S. indices finished lower Monday amid continued Russia-Ukraine uncertainty, as well as in anticipation of this week’s Fed decision. The Nasdaq composite finished lower by... 
Via Benzinga
Dexcom Snags A New Diabetes Device Win After Covid-Related Delay
Dexcom won out in Europe after the pandemic slowed its G7 CGM. 
Via Investor's Business Daily
Dexcom G7 Continuous Glucose Monitoring System Receives European CE Mark
DexCom Inc's (NASDAQ: DXCM) Dexcom G7 Continuous Glucose Monitoring (CGM) System has secured European CE Mark for people with diabetes aged two years and older... 
Via Benzinga
DexCom Stock Falls As Q4 Profit, FY22 Sales Outlook Trail Wall Street Estimates
DexCom Inc's (NASDAQ: DXCM)  
Via Benzinga
Earnings Scheduled For February 10, 2022
Companies Reporting Before The Bell • Canada Goose Hldgs (NYSE:GOOS) is projected to report quarterly earnings at $1.46 per share on revenue of $584.49 million. 
Via Benzinga
What 5 Analyst Ratings Have To Say About DexCom
Analysts have provided the following ratings for DexCom (NASDAQ:DXCM) within the last quarter: 
Via Benzinga
Could A Simple Device Help Revolutionize Medical Diagnostics? This Company Thinks So
Image provided by Know Labs This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Know... 
Via Benzinga
DexCom's Glucose Monitoring System Snags Breakthrough Device Tag For Hospital Use
The FDA granted Breakthrough Device Designation for DexCom Inc (NASDAQ: DXCM) for continuous glucose monitoring (CGM) use in the hospital setting. Dexcom CGM... 
Via Benzinga
The Daily Biotech Pulse: Adcom Recommends Additional Trials For Lilly's Partnered Cancer Drug, Novavax Touts Pediatric Vaccine Data, TC Biopharm IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adcom Rules That Lilly May Have To Conduct Additional Studies For Co-... 
Via Benzinga
Recap: DexCom Q4 Earnings
DexCom (NASDAQ:DXCM) reported its Q4 earnings results on Thursday, February 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings DexCom missed estimated earnings by... 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Q4 Gets COVID Boost, Seagen Plunges On Earnings, Adcom Test Awaits Lilly
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Where DexCom Stands With Analysts
Over the past 3 months, 6 analysts have published their opinion on DexCom (NASDAQ: 
Via Benzinga
The Week Ahead In Biotech (Feb. 6-12): Pfizer, AstraZeneca Earnings, Conference Presentations, IPOs And More
Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some big... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2022
Upgrades BTIG upgraded the previous rating for Insulet Corp (NASDAQ:PODD) from Neutral to Buy. For the third quarter, Insulet had an EPS of $0.18, compared to year-ago... 
Via Benzinga
DexCom: This Life Saving Tech Could Double Your Money In Two Years
Despite a global rise in variants of COVID-19, one of last year’s hottest plays on the pandemic shutdowns is getting absolutely slaughtered this year. 
Via Talk Markets
Expert Ratings For DexCom
Within the last quarter, DexCom (NASDAQ:DXCM) has observed the following an... 
Via Benzinga
7 Best Mutual Funds to Buy for February
Mutual funds are generally considered less risky. Here are seven mutual funds tailored to different investment objectives and risk profiles. 
Via InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For January 19, 2022
Upgrades For Rocket Companies Inc (NYSE:RKT), JP Mo... 
Via Benzinga
10 Biggest Price Target Changes For Wednesday
Raymond James cut DexCom, Inc. (NASDAQ:DXCM) pri... 
Via Benzinga
IRTC Stock: 17 Things to Know About iRhythm as Shares Rocket Higher Today
Irhythm Technologies (IRTC) stock is rising higher Monday alongside heavy trading of the shares and we know what's behind that movement! 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Molecular Partners (NASDAQ:MOLN) shares rose 26.6% to $20.9 during Monday's pre-market session. The company's market cap stands at $674.6 million. Apria (... 
Via Benzinga
IBM Artificial Intelligence Supercomputer Watson Has 8 Stock Picks For 2022
It’s the time of year that investors consider which stocks to buy and sell to build their portfolio for the next 12 months. Inflati... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE: 
Via Benzinga
Even Good Penny Stocks Like Senseonics Aren’t Always Profitable
Its latest implanted sensor lasts six months, but SENS stock faces competition from Dexcom, Abbott Labs and potentially one big name in tech. 
Via InvestorPlace
3 Reasons This Stock Could 10X in 10 Years
This healthcare company isn't done beating the market. 
Via The Motley Fool
Better Buy: DexCom or Abbott Labs?
Abbott's the heavyweight, and DexCom is the formidable challenger. 
Via The Motley Fool
5 Stocks Insiders Are Still Buying (Even As Others Cash Out)
Insider sales are generally a sign the market is about to drop, but not everyone's selling. Here are five companies with insider buying. 
Via InvestorPlace
Jim Cramer Shares His Thoughts On Innovative Industrial Properties, Nokia And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Poshmark, Inc. (NASDAQ: POSH) missed the quarter badly when others in that industry are doing quite well,... 
Via Benzinga
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.